Acutaas Chemicals shares have climbed over 200% this year, fueled by strong demand for its oncology drug intermediates. As the stock trades at 40 times its estimated FY28 earnings before interest, taxes, depreciation, and amortization, investors are evaluating the balance between its expansion into battery and semiconductor chemicals and its current high valuation.
Acutaas Chemicals has seen its share price rally more than 200% year-to-date, reflecting strong investor confidence in its specialized product portfolio. The growth is primarily supported by its advanced pharmaceutical intermediates business, which accounts for 88% of its total revenue. A major driver for this segment is the oncology drug Darolutamide, marketed as Nubeqa. Bayer, which partners with Orion Corporation on the drug, recently reported a 57% revenue increase for the product in the first quarter of fiscal year 2026. With patent exclusivity projected to last until the 2032-2038 period and new market entries such as China pending, the demand for these intermediates remains a core focus for the company.
Capacity Expansion and New Business Segments
The company is actively working to diversify its revenue streams through its Specialty Chemicals segment, which currently contributes 12% to total sales. A key area of development is battery chemicals, specifically the production of electrolyte additives like Vinylene Carbonate and Fluoroethylene Carbonate. Acutaas Chemicals has secured three-year contracts for its initial capacity and is currently progressing with a second phase of expansion, expected to be complete in the first half of fiscal year 2027. Additionally, the company is building a pipeline of over ten new products in this space.
In the semiconductor chemicals sector, the company's subsidiary, Baba Fine Chemicals, has shown a notable turnaround. In the fourth quarter, operating margins for the Specialty Chemicals segment rose to 29%, up from 12% in the previous period. This improvement was driven by high performance in photoresist chemicals. To further its reach in the semiconductor market, Acutaas Chemicals has invested Rs 190 crore in a South Korean joint venture named Indichem, aimed at developing advanced materials and deepening regional client relationships.
Financial Outlook and Valuation Considerations
Management has set a target of Rs 1,000 crore in revenue from its CDMO (Contract Development and Manufacturing Organization) business by fiscal year 2028. While the company projects annual top-line growth exceeding 25% over the medium term, its ability to maintain profit margins will be linked to the successful execution of these new projects and the steady commissioning of its Ankaleshwar site, which is currently operating at 31% utilization.
Investors are now weighing the company's growth prospects against its current market valuation, which stands at 40 times its estimated FY28 Enterprise Value to EBITDA. Given the sharp rise in the stock price over the past year, some market observers have pointed to the risk that near-term growth expectations may already be priced in. The primary focus for investors moving forward will be the company’s ability to scale its battery and semiconductor chemical ventures while maintaining the operational efficiency needed to sustain its current margin profile.